



Providing gold standard disinfection and decontamination technology through the design, development and global deployment of our state-of-the-art SteraMist product line and services

**KEY FINANCIAL STATISTICS**

**170%**  
SEQUENTIAL REVENUE GROWTH IN 2Q24

**61.5%**  
GROSS MARGIN\*

**\$6.8M**  
IN WORKING CAPITAL\*

At June 30, 2024

**INVESTMENT HIGHLIGHTS**

**CUTTING EDGE TECHNOLOGY**

- TOMI BIT is the industry's ONLY low-percentage hydrogen peroxide solution capable of delivering six log kill with a dwell time of seconds
- No compromise to human health or adversely affecting medical and lab equipment

**EXPANDING MARKET DEMAND**

- Additional market verticals including food safety and cannabis
- Global Surface Disinfectant Market expected to grow at a CAGR of 5.46% from 2023-2028; expected to reach \$6.29 billion by 2028
- Growing partner of choice for government and military facilities

**GLOBAL CUSTOMER BASE**

- Life Sciences, hospitals, healthcare facilities, bio laboratories, state/local institutions, schools, restoration partners, sports organizations, offices, aerospace partners and more
- Rising demand from Asia, Europe & Middle East

**SKILLED MANAGEMENT TEAM**

- CEO Dr. Halden Shane brings extensive medical and business leadership experience
- Proven success delivering on business, operations and regulatory milestones
- Transformed TOMI's SteraMist Technology to industry standard of disinfection and decontamination technology

**REVOLUTIONARY PRODUCT LINE**

- The SteraPak is the most mobile SteraMist unit available on the market
- Custom Engineered Systems and the new SteraMist Hybrid eliminate human error and increase disinfection accuracy
- The new SteraMist Transport and NV+ cut downtime and provide full coverage disinfection without damage to equipment
- SteraMist Integrated Systems are designed to provide reliable decontamination to any lab space including high-quality cleanrooms, high containment areas

**SUCCESSFUL BUSINESS MODEL**


- Recurring revenue stream from sales of BIT solution
- High margin razor/razor blade model
- Capital efficient business infrastructure

**DIVISIONS**



**UNIQUE NON-CORROSIVE TECHNOLOGY**

**SteraMist BIT** contains no corrosive toxic chemicals, no harmful silver ions, and no watery residue



**REGISTRATIONS & INTELLECTUAL PROPERTY**



**32**  
GRANTED PATENTS

**50**  
PATENTS APPLICATIONS WORLDWIDE

# CUTTING EDGE IONIZED HYDROGEN PEROXIDE PROCESS

## 1. COLD PLASMA




7.8% hydrogen peroxide BIT Solution converts to iHP after passing through a cold plasma arc.

## 2. DISPERSION




iHP is carried throughout the mist, moving like a gas throughout the treated area.

## 3. CONTACT



iHP damages pathogenic organisms through oxidation of proteins, carbohydrates, and lipids.

## 4. DISRUPTION




Cellular disruptions and/or dysfunctions occur and allows for disinfection & decontamination in the targeted area.

## MARKET DEMAND

- The Global Surface Disinfectant Market is expected to grow from \$4.83 billion in 2023 to \$6.29 billion by 2028, representing a CAGR of 5.46% during the forecast period\*
- Demand for effective disinfection products has grown consistently since 2014 as a result of the proliferation of hospital acquired infections and growing food safety concerns
- TOMI can deliver disinfection/decontamination that is highly effective (six log kill), fast acting and safe

### Global Surface Disinfectant Market Size (In \$ Billions)



## REPRESENTATIVES/DISTRIBUTORS WORLDWIDE



## CLIENTS SPANNING MULTIPLE INDUSTRIES



## CONTACT INFO

**TOMI ENVIRONMENTAL SOLUTIONS, INC. | STERAMIST**  
 8430 Spires Way Suite N  
 Frederick, MD 21701  
 steramist.com

**IMS INVESTOR RELATIONS**  
 John Nesbett/Rosalyn Christian  
 203-972-9200  
 tomi@imsinvestorrelations.com

## SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

This fact sheet contains forward-looking statements that are based on current expectations, estimates, forecasts and projections of future performance based on management's judgment, beliefs, current trends, and anticipated product performance. These forward-looking statements include, without limitation, statements relating to the benefit of collaboration with Sterile Grow and business opportunities of TOMI's products in the cannabis and food markets. Forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These factors include, but are not limited to, our ability to market and sell our products to customers; our ability to maintain and manage growth and generate sales, our reliance on a single or a few products for a majority of revenues; the general business and economic conditions; and other risks as described in our SEC filings, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2022 filed by us with the SEC and other periodic reports we filed with the SEC. The information provided in this document is based upon the facts and circumstances known at this time. Other unknown or unpredictable factors or underlying assumptions subsequently proving to be incorrect could cause actual results to differ materially from those in the forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, or achievements. You should not place undue reliance on these forward-looking statements. All information provided in this press release is as of today's date, unless otherwise stated, and we undertake no duty to update such information, except as required under applicable law.